Parvo-Vac (Canada)This page contains information on Parvo-Vac for veterinary use.
The information provided typically includes the following:
- Parvo-Vac Indications
- Warnings and cautions for Parvo-Vac
- Direction and dosage information for Parvo-Vac
Parvo-VacThis treatment applies to the following species:
For use in swine only
PRODUCT DESCRIPTION: Parvo-Vac is for vaccination of healthy swine as an aid in preventing reproductive failure caused by porcine parvovirus (PPV). The vaccine is prepared by chemically inactivating a porcine parvovirus strain grown in an established swine cell line, and combining the viral fluids with a sterile adjuvant.
DISEASE DESCRIPTION: PPV is a major cause of swine reproductive failure. Infection in susceptible swine is generally subclinical. However, infection of pregnant females may involve the developing fetus. Stillbirths, mummified fetuses, embryonic death, and infertility (SMEDI) are the chief manifestations of the disease. Reproductive failure generally occurs when susceptible females are exposed during the first 70 days of gestation. Thereafter, the fetuses may survive in utero infection. The PPV agent is enzootic in the United States1 and has a worldwide distribution. Thus, a large proportion of adult swine carry antibodies or disseminate the virus.2 When maternally acquired antibodies decline below protective levels, stock is at risk.
SAFETY AND EFFICACY: Postvaccination reactions were not observed in experimental pigs vaccinated with Parvo-Vac or in swine vaccinated under field conditions in extensively safety trials. In efficacy studies, vaccination of seronegative gilts before breeding protected 95.7% of developing fetuses from infection and death after challenge with virulent PPV. In contrast, 46.3% of the fetuses from nonvaccinated control gilts became infected and died following the same challenge. Previous studies have shown that PPV vaccination can produce consistent protection despite low hemagglutination inhibition antibody titers.3
Directions For Use
1. General Directions: Shake well. Aseptically administer 2 mL intramuscularly.
2. Primary Vaccination: Administer a single 2-mL dose to healthy sows 14-60 days before breeding. Healthy gilts, however, should receive a single 2-mL dose as near as possible to 14 days before breeding; if gilts are vaccinated sooner, persisting maternal antibodies may interfere with vaccination.
3. Revaccination: Semiannual revaccination with a single dose before breeding is recommended.
4. Good animal husbandry and herd health management practices should be employed.
1. Store at 2°-7°C. Prolonged exposure to higher temperatures may adversely affect potency. Do not freeze.
2. Use entire contents when first opened.
3. Sterilized syringes and needles should be used to administer this vaccine.
4. Do not vaccinate within 21 days before slaughter.
5. Contains gentamicin as preservative.
6. As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.
7. This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.
1. Mengeling WL: Porcine Parvovirus: Frequency of naturally occurring transplacental infection and viral contamination of fetal porcine kidney cell cultures. Am J Vet Res 36:41-44, 1975.
2. Johnson RH, Donaldson-Wood CR, Joo HS, et al: Observations on the epidemiology of porcine parvovirus. Austr Vet J 52:80-84, 1976.
3. Mengeling WL, Brown TT, Paul PS, et al: Efficacy of an inactivated virus vaccine for prevention of porcine parvovirus-induced reproductive failure. Am J Vet Res 40:204-207, 1979.
Technical inquiries should be directed to Pfizer Animal Health Technical Services, (800) 366-5288 (USA), (800) 461-0917 (Canada).
For veterinary use only
U.S. Veterinary License No. 189
Pfizer Animal Health, Exton, PA 19341, USA, Div. of Pfizer Inc., NY, NY 10017
® Registered trademark of Pfizer Products Inc; Pfizer Canada Inc., licensee
Presentation: Available in 10 dose vials.
NAC No.: 11980694
16,740 TRANS-CANADA HIGHWAY, KIRKLAND, QC, H9H 4M7
|Technical Services Canada:||800-461-0917|
|Technical Services USA:||800-366-5288|
|Every effort has been made to ensure the accuracy of the Parvo-Vac information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.|
Copyright © 2015 North American Compendiums. Updated: 2014-12-03